Safeway Inc. (NYSE: SWY) – For an in-depth report on Safeway Inc. follow: www.BullTrends.com/stockquote/SWY
Shares of Safeway Inc. closed up a modest 2.05% on Thursday with nearly 21 million shares traded. The stock was one of the most active stocks in the NYSE market and came just 15 cents shy of its 52-week high during intra-day trading. The company announced that it was looking to sell itself. Safeway Inc. said that it is in ongoing discussions regarding a possible sale, though it warned the talks may not result in a deal. The company reported fourth-quarter earnings on Wednesday of 53 cents a share; analysts surveyed by Thomson Reuters expected earnings of 48 cents a share.
Arris Enterprises, Inc. (NASDAQ: ARRS) – For an in-depth report on Arris Enterprises, Inc. follow: www.BullTrends.com/stockquote/ARRS
Arris Enterprises closed up 12.17% on Thursday with about 6.1 million shares traded. The stock was one of the biggest gainers on the NASDAQ and hit a new high of $31.42 during intra-day trading. The company released impressive financial results for the fourth quarter of 2013, significantly beating the Zacks Consensus Estimate. GAAP net loss in the fourth quarter of 2013 was $2.9 million or a loss of 2 cents per share compared with a net income of $14.8 million or 13 cents per share in the prior-year quarter. Quarterly adjusted (excluding special items) earnings per share came in at 49 cents, significantly above the Zacks Consensus Estimate of 42 cents. Quarterly revenues totaled $1,199.1 million, up a whopping 248.6% year over year and well above the Zacks Consensus Estimate of $1,164 million.
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV) – For an in-depth report on ContraVir Pharmaceuticals, Inc. follow: www.BullTrends.com/stockquote/CTRV
ContraVir Pharmaceuticals closed down 19.46% and was one of the biggest decliners in the OTCBB market on Thursday. The company had no news released to explain the sudden fall. ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to treat herpes zoster disease.
Onconova Therapeutics, Inc. (NASDAQ: ONTX) – For an in-depth report on Onconova Therapeutics, Inc. follow: www.BullTrends.com/stockquote/ONTX
Shares of Onconova Therapeutics plummeted 36.58% on Thursday on about 3.3 million shares. The stock hit a new 52-week low of $7.75 during intra-day trading and was one of the biggest decliners in the NASDAQ. The company dropped as much as 44% after the company announced disappointing results from its phase 3 ONTIME trial of rigosertib in higher-risk myelodysplastic syndrome, or MDS, patients who had progressed or relapsed while using hypomethylating agents, or HMA.
Wondering what your next move should be in the market? BullTrends.com can help lead the way. For free access to our complete stock reports, take a few minutes to register with us by clicking this link: http://www.bulltrends.com/
Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.